Short-duration therapy with daclatasvir/asunaprevir/beclabuvir fixed-dose combination plus sofosbuvir in patients with chronic hepatitis C genotype 1 (FOURward Study)

被引：0
|
作者：
Sulkowski, Mark S. [1 ]
Flamm, Steven L. [2 ]
Kayali, Zeid [3 ]
Lawitz, Eric [4 ]
Kwo, Paul Y. [5 ]
McPhee, Fiona [6 ]
Torbeyns, Anne [7 ]
Hughes, Eric A. [8 ]
Swenson, Eugene S. [6 ]
Yin, Philip [6 ]
Linaberry, Misti [8 ]
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Northwestern Univ, Chicago, IL 60611 USA
[3] Inland Empire Liver Fdn, Rialto, CA USA
[4] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA
[5] Indiana Univ, Indianapolis, IN 46204 USA
[6] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[7] Bristol Myers Squibb, Braine Lalleud, Belgium
[8] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
702
引用
收藏
页码：556A / 556A
页数：1
相关论文
共 50 条
  • [1] Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study)
    Sulkowski, Mark S.
    Flamm, Steve
    Kayali, Zeid
    Lawitz, Eric J.
    Kwo, Paul
    McPhee, Fiona
    Torbeyns, Anne
    Hughes, Eric A.
    Swenson, Eugene S.
    Yin, Philip D.
    Linaberry, Misti
    LIVER INTERNATIONAL, 2017, 37 (06) : 836 - 842
  • [2] Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with genotype 1 chronic hepatitis C
    Thiam, A.
    Conway, B.
    DRUGS OF TODAY, 2018, 54 (04) : 237 - 244
  • [3] Modeling time to cure after short-duration treatment for chronic HCV with daclatasvir, asunaprevir, beclabuvir and sofosbuvir: the FOURward study
    Deng, B.
    Lou, S.
    Dubey, P.
    Etzion, O.
    Chayam, K.
    Uprichard, S. L.
    Sulkowski, M.
    Cotler, S. J.
    Dahari, H.
    JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 58 - 58
  • [4] Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1
    Kao, Jia-Horng
    Yu, Ming-Lung
    Peng, Cheng-Yuan
    Heo, Jeong
    Chu, Chi-Jen
    Chang, Ting-Tsung
    Lee, Youn-Jae
    Hu, Tsung-Hui
    Yoon, Ki Tae
    Paik, Seung Woon
    Lim, Young Suk
    Ahn, Sang Hoon
    Isakov, Vasily
    McPhee, Fiona
    Hu, Wenhua
    Swenson, Eugene Scott
    Yin, Philip D.
    Treitel, Michelle
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (12) : 1998 - 2005
  • [5] Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection
    Poordad, Fred
    Sievert, William
    Mollison, Lindsay
    Bennett, Michael
    Tse, Edmund
    Braeu, Norbert
    Levin, James
    Sepe, Thomas
    Lee, Samuel S.
    Angus, Peter
    Conway, Brian
    Pol, Stanislas
    Boyer, Nathalie
    Bronowicki, Jean-Pierre
    Jacobson, Ira
    Muir, Andrew J.
    Reddy, K. Rajender
    Tam, Edward
    Ortiz-Lasanta, Grisell
    de Ledinghen, Victor
    Sulkowski, Mark
    Boparai, Navdeep
    McPhee, Fiona
    Hughes, Eric
    Swenson, E. Scott
    Yin, Philip D.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (17): : 1728 - 1735
  • [6] Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection
    Toyota, Joji
    Karino, Yoshiyasu
    Suzuki, Fumitaka
    Ikeda, Fusao
    Ido, Akio
    Tanaka, Katsuaki
    Takaguchi, Koichi
    Naganuma, Atsushi
    Tomita, Eiichi
    Chayama, Kazuaki
    Fujiyama, Shigetoshi
    Inada, Yukiko
    Yoshiji, Hitoshi
    Watanabe, Hideaki
    Ishikawa, Hiroki
    Hu, Wenhua
    McPhee, Fiona
    Linaberry, Misti
    Yin, Philip D.
    Swenson, Eugene Scott
    Kumada, Hiromitsu
    JOURNAL OF GASTROENTEROLOGY, 2017, 52 (03) : 385 - 395
  • [7] Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection
    Joji Toyota
    Yoshiyasu Karino
    Fumitaka Suzuki
    Fusao Ikeda
    Akio Ido
    Katsuaki Tanaka
    Koichi Takaguchi
    Atsushi Naganuma
    Eiichi Tomita
    Kazuaki Chayama
    Shigetoshi Fujiyama
    Yukiko Inada
    Hitoshi Yoshiji
    Hideaki Watanabe
    Hiroki Ishikawa
    Wenhua Hu
    Fiona McPhee
    Misti Linaberry
    Philip D. Yin
    Eugene Scott Swenson
    Hiromitsu Kumada
    Journal of Gastroenterology, 2017, 52 : 385 - 395
  • [8] Efficacy and safety of a fixed dose combination tablet of asunaprevir plus beclabuvir plus daclatasvir for the treatment of Hepatitis C
    Zappulo, Emanuela
    Scotto, Riccardo
    Buonomo, Antonio Riccardo
    Maraolo, Alberto Enrico
    Pinchera, Biagio
    Gentile, Ivan
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (03) : 261 - 273
  • [9] Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C
    Esposito, Isabella
    Marciano, Sebastian
    Trinks, Julieta
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (06) : 649 - 657
  • [10] Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1
    Kumari, Radhika
    Nguyen, Mindie H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (05) : 739 - 748
12345